Developers are encouraged by the robust anti-tumor potency demonstrated by their novel chimeric receptor, the Dual-targeting Synthetic TCR and Antigen Receptor (D-STAR).
Despite ongoing concerns, results from a French database study characterize the risk of secondary cancers after chimeric antigen receptor (CAR) T-cell therapy as very low.